Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares Bought by Jane Street Group LLC

Jane Street Group LLC lifted its holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 106.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,872 shares of the company’s stock after buying an additional 36,028 shares during the period. Jane Street Group LLC owned approximately 0.15% of Verrica Pharmaceuticals worth $101,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Quest Partners LLC acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth approximately $50,000. Verition Fund Management LLC acquired a new stake in Verrica Pharmaceuticals during the third quarter worth about $89,000. Rhumbline Advisers raised its stake in Verrica Pharmaceuticals by 20.4% during the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock worth $194,000 after purchasing an additional 4,514 shares during the period. Renaissance Technologies LLC acquired a new position in Verrica Pharmaceuticals in the 2nd quarter valued at about $332,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Verrica Pharmaceuticals by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock valued at $428,000 after buying an additional 4,393 shares during the period. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Stock Performance

NASDAQ VRCA opened at $0.66 on Wednesday. The company has a debt-to-equity ratio of 29.58, a current ratio of 1.34 and a quick ratio of 1.22. The company has a market cap of $29.90 million, a P/E ratio of -0.36 and a beta of 1.49. The stock has a 50-day moving average of $0.85 and a two-hundred day moving average of $2.70. Verrica Pharmaceuticals Inc. has a 1-year low of $0.61 and a 1-year high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Monday, November 4th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.12). The business had revenue of ($1.78) million for the quarter, compared to analysts’ expectations of $7.53 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. As a group, analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.42 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Royal Bank of Canada lowered shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $11.00 to $2.00 in a research report on Tuesday, November 5th. TD Cowen decreased their price target on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, October 21st. HC Wainwright downgraded Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Friday, December 20th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.50.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.